Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,011 across all filing types
Latest filing 2022-11-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于子公司收到行政处罚决定书的公告
Regulatory Filings Classification · 100% confidence The document is an announcement from Kangzhi Pharmaceutical Co., Ltd. regarding an administrative penalty received by its subsidiary for environmental violations. It details the nature of the penalty, the legal basis, the fine amount, and the company's response and impact assessment. The document is short (1707 characters) and focuses on disclosing a regulatory event rather than providing a full report or financial statements. It does not contain financial data or detailed management discussion but is a formal regulatory announcement about an administrative penalty. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance disclosures that do not fit other specific categories.
2022-11-28 Chinese
独立董事关于第五届董事会第二十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters related to the 29th meeting of the 5th board of directors of 康芝药业股份有限公司. It discusses the nomination and election procedures for board candidates, compliance with company law and regulations, and the qualifications of the candidates. There is no financial data, earnings information, or report publication mentioned. The content focuses on board/management changes and governance matters. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication, so it is not RPA or RNS.
2022-11-28 Chinese
独立董事工作制度 （2022年度修订）
Governance Information Classification · 100% confidence The document is titled '独立董事工作制度' which translates to 'Independent Director Work System' and details the rules, responsibilities, qualifications, nomination, and remuneration of independent directors in the company 康芝药业股份有限公司. It references relevant laws, regulations, and governance practices related to independent directors. There is no financial data, earnings information, or report publication announcement. The content is focused on governance structure and internal rules regarding independent directors, which aligns with Governance Information filings. The document is about the company's internal governance practices rather than a report or announcement of financial results or management changes.
2022-11-28 Chinese
2022年第一次临时股东大会通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2022 first extraordinary general meeting of shareholders for 康芝药业股份有限公司. It includes information about the meeting date, location, voting procedures (both onsite and online), agenda items including board and supervisory committee elections, and instructions for shareholder registration and proxy voting. The document does not contain financial statements or financial performance data, nor is it a transcript or presentation. It is a formal notice to shareholders about the meeting and the matters to be voted on. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA) or a Proxy Solicitation & Information Statement (PSI). However, since it is a notice about the meeting and voting procedures rather than the solicitation materials or proxy statement itself, and it is not the voting results, it is best classified as a Proxy Solicitation & Information Statement (PSI) because it provides detailed information to shareholders to inform and request votes for the meeting.
2022-11-28 Chinese
独立董事候选人声明（吴清和）
Board/Management Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Kangzhi Pharmaceutical Co., Ltd. It contains detailed statements confirming the candidate's qualifications and compliance with various regulatory requirements for serving as an independent director. There are no financial statements, earnings data, or report summaries. The document is a regulatory compliance statement related to board/management qualifications rather than an announcement of board changes or a management report. It is not a report publication announcement or a certification letter but a declaration related to board membership qualifications. Given the content, the most appropriate classification is 'Board/Management Information' (MANG), as it pertains to board member candidacy and related disclosures. The document length is 3285 characters, which is relatively short but contains substantive content about board membership qualifications, not just a brief announcement or certification.
2022-11-28 Chinese
募集资金管理制度 （2022年度修订）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the internal rules, procedures, and regulatory compliance related to the management, storage, use, and supervision of funds raised by the company through securities issuance. It references relevant laws and stock exchange rules, outlines the responsibilities of the board and management, and specifies reporting and disclosure requirements. The content is a governance framework document rather than a financial report, announcement, or presentation. It does not contain financial statements, earnings data, or voting results. It is a detailed governance and compliance policy document related to capital management. Therefore, the most appropriate classification is Governance Information (CGR).
2022-11-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.